Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Analyst Upgrades and Downgrades
HZNP has been the subject of several research reports. BMO Capital Markets decreased their price objective on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an "outperform" rating for the company in a research note on Thursday, August 4th. UBS Group lowered shares of Horizon Therapeutics Public from a "buy" rating to a "neutral" rating and decreased their target price for the company from $137.00 to $71.00 in a research report on Thursday, August 4th. Oppenheimer restated a "buy" rating and set a $140.00 price objective on shares of Horizon Therapeutics Public in a research report on Friday, July 8th. StockNews.com lowered shares of Horizon Therapeutics Public from a "buy" rating to a "hold" rating in a research report on Friday, August 5th. Finally, Morgan Stanley lowered their price target on Horizon Therapeutics Public from $135.00 to $90.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $117.22.
Horizon Therapeutics Public Price Performance
Horizon Therapeutics Public stock traded up $0.37 during midday trading on Friday, hitting $67.47. 2,963,284 shares of the company's stock were exchanged, compared to its average volume of 3,328,654. Horizon Therapeutics Public has a 52-week low of $60.76 and a 52-week high of $120.54. The stock has a 50-day moving average price of $80.67 and a two-hundred day moving average price of $92.69. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.79 and a current ratio of 4.05. The company has a market cap of $15.54 billion, a P/E ratio of 20.82, a PEG ratio of 1.67 and a beta of 1.12.
Horizon Therapeutics Public (NASDAQ:HZNP - Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 EPS for the quarter, missing analysts' consensus estimates of $1.36 by ($0.29). The business had revenue of $876.40 million for the quarter, compared to the consensus estimate of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.62 EPS. On average, equities research analysts forecast that Horizon Therapeutics Public will post 4.27 earnings per share for the current year.
Insider Buying and Selling
In other Horizon Therapeutics Public news, EVP Sean M. Clayton acquired 745 shares of the business's stock in a transaction on Thursday, August 4th. The shares were bought at an average price of $66.67 per share, with a total value of $49,669.15. Following the transaction, the executive vice president now directly owns 745 shares of the company's stock, valued at approximately $49,669.15. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Horizon Therapeutics Public news, EVP Sean M. Clayton purchased 745 shares of the firm's stock in a transaction on Thursday, August 4th. The stock was bought at an average cost of $66.67 per share, for a total transaction of $49,669.15. Following the completion of the purchase, the executive vice president now owns 745 shares in the company, valued at approximately $49,669.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Timothy P. Walbert sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $92.48, for a total value of $2,312,000.00. Following the completion of the sale, the chief executive officer now directly owns 435,549 shares in the company, valued at $40,279,571.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,784 shares of company stock valued at $7,350,633. Corporate insiders own 2.50% of the company's stock.
